Core Viewpoint - The article highlights the advancements of Kewang Pharmaceutical's self-developed "Macrophage Connector Platform BiME" and emphasizes the need for innovative capabilities and global competitiveness in the pharmaceutical industry, particularly in the context of increasing homogeneity among products [1][2]. Company Summary - Kewang Pharmaceutical, founded 8 years ago in Pudong, focuses on key targets in oncology and autoimmune diseases, with a pipeline of immune therapies that have global competitiveness, including 4 FIC and BIC products in various clinical stages and several preclinical pipelines, with plans to list on the Hong Kong stock market this year [1]. - In 2023, Kewang Pharmaceutical entered a global collaboration with AstraZeneca worth over $1.7 billion, aimed at advancing the BiME platform, which targets the tumor microenvironment and aims to activate macrophages for treating cancers like liver and stomach cancer that lack effective therapies [2]. Industry Summary - The capital market shows strong interest in innovative pharmaceutical companies, as evidenced by Jinfang Pharmaceutical's IPO in Hong Kong, which raised $268 million, marking the largest fundraising in the Hong Kong 18A sector since 2022 [4]. - In the first half of this year, Pudong's biopharmaceutical companies engaged in nearly 30 outbound transactions, accounting for 31% of the national total and 14% of the global total [4]. - The Pudong New Area has recently announced a plan to enhance its biopharmaceutical industry, aiming to become a global hub for innovative drug and device launches, as well as a preferred location for scientists' innovation and entrepreneurship [5].